董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lisa A. Conte | 女 | Chief Executive Officer, President and Director | 66 | 87.53万美元 | 30.60 | 2025-07-08 |
| James J. Bochnowski | 男 | Chairman of the Board | 81 | 13.26万美元 | 19.03 | 2025-07-08 |
| Jonathan B. Siegel | 男 | Director | 51 | 9.77万美元 | 未持股 | 2025-07-08 |
| Anula Jayasuriya | 女 | Director | 68 | 6.89万美元 | 未持股 | 2025-07-08 |
| John Micek III | 男 | Director | 72 | 9.52万美元 | 6.41 | 2025-07-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lisa A. Conte | 女 | Chief Executive Officer, President and Director | 66 | 87.53万美元 | 30.60 | 2025-07-08 |
| Steven R. King | 男 | Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary | 67 | 51.59万美元 | 10.74 | 2025-07-08 |
| Carol R. Lizak | 女 | Chief Financial Officer | 61 | 未披露 | 未持股 | 2025-07-08 |
| Jonathan S. Wolin | 男 | Chief of Staff, General Counsel and Chief Compliance Officer | 64 | 57.42万美元 | 未持股 | 2025-07-08 |
| Pravin Chaturvedi | 男 | Chief Scientific Officer | 62 | 64.66万美元 | 未持股 | 2025-07-08 |
董事简历
中英对照 | 中文 | 英文- Lisa A. Conte
-
Lisa A. Conte，自2001年11月成立Napo以来，担任首席执行官和董事会成员；自2021年3月成立以来，担任Jaguar Health， Inc.控股子公司Napo Therapeutics， S.p.A （f/k/a Napo EU S.p.A）（“Napo Therapeutics”）的董事会主席。1989年，她创立了Shaman Pharmaceuticals， Inc.，这是一家天然产品制药公司。她目前也是加州非营利公益公司Healing Forest Conservatory的董事会成员，并担任Life Science Leader杂志的编辑顾问委员会和Pure Earth领导委员会的成员。Conte女士持有California大学， San Diego的生理学和药理学硕士学位，以及Dartmouth College的生物化学工商管理硕士和学士学位。
Lisa A. Conte,serves as the Chief Executive Officer and a member of the board of Napo since she founded Napo in November 2001 and is the Chairman of the board of Jaguar Health, Inc. majority owned subsidiary Napo Therapeutics, S.p.A. (f/k/a Napo EU S.p.A.) ("Napo Therapeutics") since its inception in March 2021. In 1989, Ms. Conte founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company. Ms. Conte is also currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation, and serves on the Editorial Advisory Board of Life Science Leader magazine and on the Leadership Council of Pure Earth. Ms. Conte holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College. - Lisa A. Conte，自2001年11月成立Napo以来，担任首席执行官和董事会成员；自2021年3月成立以来，担任Jaguar Health， Inc.控股子公司Napo Therapeutics， S.p.A （f/k/a Napo EU S.p.A）（“Napo Therapeutics”）的董事会主席。1989年，她创立了Shaman Pharmaceuticals， Inc.，这是一家天然产品制药公司。她目前也是加州非营利公益公司Healing Forest Conservatory的董事会成员，并担任Life Science Leader杂志的编辑顾问委员会和Pure Earth领导委员会的成员。Conte女士持有California大学， San Diego的生理学和药理学硕士学位，以及Dartmouth College的生物化学工商管理硕士和学士学位。
- Lisa A. Conte,serves as the Chief Executive Officer and a member of the board of Napo since she founded Napo in November 2001 and is the Chairman of the board of Jaguar Health, Inc. majority owned subsidiary Napo Therapeutics, S.p.A. (f/k/a Napo EU S.p.A.) ("Napo Therapeutics") since its inception in March 2021. In 1989, Ms. Conte founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company. Ms. Conte is also currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation, and serves on the Editorial Advisory Board of Life Science Leader magazine and on the Leadership Council of Pure Earth. Ms. Conte holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College.
- James J. Bochnowski
-
James J. Bochnowski，自2014年2月起担任Jaguar Health, Inc.董事会成员，自2014年6月起担任Jaguar Health, Inc.董事会主席。2014年2月以来，他还担任Jaguar Health, Inc.全资子公司Napo Pharmaceuticals, Inc.（“Napo”）的董事会成员。1988年以来，他曾担任Delphi Ventures（风险投资公司）的创始人和管理成员。1980年，Bochnowski先生共同创立了Technology Venture Investors。Bochnowski先生持有Harvard University Graduate School of Business的工商管理硕士学位和Massachusetts Institute of Technology的航空航天学士学位。
James J. Bochnowski,serves as a member of the board of directors of Jaguar Health, Inc. wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), since February 2014. Since 1988, Mr. Bochnowski has served as the founder and Managing Member of Delphi Ventures, a venture capital firm. In 1980, Mr. Bochnowski co-founded Technology Venture Investors. Mr. Bochnowski holds an M.B.A. with distinction from Harvard University Graduate School of Business and a B.S. in Aeronautics and Astronautics from Massachusetts Institute of Technology. - James J. Bochnowski，自2014年2月起担任Jaguar Health, Inc.董事会成员，自2014年6月起担任Jaguar Health, Inc.董事会主席。2014年2月以来，他还担任Jaguar Health, Inc.全资子公司Napo Pharmaceuticals, Inc.（“Napo”）的董事会成员。1988年以来，他曾担任Delphi Ventures（风险投资公司）的创始人和管理成员。1980年，Bochnowski先生共同创立了Technology Venture Investors。Bochnowski先生持有Harvard University Graduate School of Business的工商管理硕士学位和Massachusetts Institute of Technology的航空航天学士学位。
- James J. Bochnowski,serves as a member of the board of directors of Jaguar Health, Inc. wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), since February 2014. Since 1988, Mr. Bochnowski has served as the founder and Managing Member of Delphi Ventures, a venture capital firm. In 1980, Mr. Bochnowski co-founded Technology Venture Investors. Mr. Bochnowski holds an M.B.A. with distinction from Harvard University Graduate School of Business and a B.S. in Aeronautics and Astronautics from Massachusetts Institute of Technology.
- Jonathan B. Siegel
-
JonathanB.Siegel于2018年9月13日成为我们的董事会成员。Siegel先生自2017年成立以来一直担任JBS梦百合Ventures的创始人兼首席执行官。此前，他曾于2011年至2017年担任金登资本管理（Kingdon Capital Management）合伙人兼梦百合部门主管。在加入Kingdon之前，Siegel先生从2005年到2011年担任SAC Capital Advisors的梦百合投资组合经理；Stearns&Co.是Dresdner Kleinwort Wasserstein的制药研究助理，也是美国计算机科学公司生命科学部的顾问。Siegel先生曾在哈佛医学院诺华免疫生物学中心（Novartis Center for Immunobiology）担任研究助理，并在塔夫茨大学医学院（Tufts University School of Medicine）担任研究助理。他也是纳斯达克上市公司JaguarHealth，Inc.的董事，并自2019年3月起担任私人制药公司Vitalis LLC的顾问委员会成员。Siegel先生于1995年获得塔夫茨大学（Tufts University）心理学学士学位，并于1999年获得哥伦比亚商学院（Columbia Business School）工商管理硕士学位。
Jonathan B. Siegel,has served as the Chief Executive Officer of JBS Healthcare Ventures, which pursues investments in public and private healthcare entities, since he founded the company in 2017. In June 2021, he also assumed the role of CEO and Chairman of the board of OPY Acquisition Corp. I, a public Nasdaq-listed company until December 2023. Mr. Siegel is also a Senior Strategic Advisor to astr partners since December 2024, a Co-Founder and Advisor to Incregen Therapeutics since 2023 and a Strategic Advisor to Ciba Health since December 2024. From 2011 until 2017, he was a partner and healthcare sector head at Kingdon Capital Management. Prior to joining Kingdon, Mr. Siegel was a healthcare portfolio manager at SAC Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical research at Bear, Stearns & Co.; a pharmaceuticals research associate at Dresdner Kleinwort Wasserstein; and a consultant in the Life Sciences Division of Computer Sciences Corporation. Mr. Siegel worked as a research associate at the Novartis Center for Immunobiology at Harvard Medical School and as a research assistant at Tufts University School of Medicine. He has served on the board of advisors of Vitalis LLC, a private pharmaceutical company, since 2019. Previously he served on the Board of Directors of Sol-Gel Technologies Ltd, a Nasdaq-listed company from 2018 to 2024, and served on the Board of Directors of Lumara Health. Mr. Siegel received a BS in Psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999. - JonathanB.Siegel于2018年9月13日成为我们的董事会成员。Siegel先生自2017年成立以来一直担任JBS梦百合Ventures的创始人兼首席执行官。此前，他曾于2011年至2017年担任金登资本管理（Kingdon Capital Management）合伙人兼梦百合部门主管。在加入Kingdon之前，Siegel先生从2005年到2011年担任SAC Capital Advisors的梦百合投资组合经理；Stearns&Co.是Dresdner Kleinwort Wasserstein的制药研究助理，也是美国计算机科学公司生命科学部的顾问。Siegel先生曾在哈佛医学院诺华免疫生物学中心（Novartis Center for Immunobiology）担任研究助理，并在塔夫茨大学医学院（Tufts University School of Medicine）担任研究助理。他也是纳斯达克上市公司JaguarHealth，Inc.的董事，并自2019年3月起担任私人制药公司Vitalis LLC的顾问委员会成员。Siegel先生于1995年获得塔夫茨大学（Tufts University）心理学学士学位，并于1999年获得哥伦比亚商学院（Columbia Business School）工商管理硕士学位。
- Jonathan B. Siegel,has served as the Chief Executive Officer of JBS Healthcare Ventures, which pursues investments in public and private healthcare entities, since he founded the company in 2017. In June 2021, he also assumed the role of CEO and Chairman of the board of OPY Acquisition Corp. I, a public Nasdaq-listed company until December 2023. Mr. Siegel is also a Senior Strategic Advisor to astr partners since December 2024, a Co-Founder and Advisor to Incregen Therapeutics since 2023 and a Strategic Advisor to Ciba Health since December 2024. From 2011 until 2017, he was a partner and healthcare sector head at Kingdon Capital Management. Prior to joining Kingdon, Mr. Siegel was a healthcare portfolio manager at SAC Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical research at Bear, Stearns & Co.; a pharmaceuticals research associate at Dresdner Kleinwort Wasserstein; and a consultant in the Life Sciences Division of Computer Sciences Corporation. Mr. Siegel worked as a research associate at the Novartis Center for Immunobiology at Harvard Medical School and as a research assistant at Tufts University School of Medicine. He has served on the board of advisors of Vitalis LLC, a private pharmaceutical company, since 2019. Previously he served on the Board of Directors of Sol-Gel Technologies Ltd, a Nasdaq-listed company from 2018 to 2024, and served on the Board of Directors of Lumara Health. Mr. Siegel received a BS in Psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999.
- Anula Jayasuriya
-
Anula Jayasuriya是ExxClaim Capital的创始人兼董事总经理，这是一家早期风险基金，专注于促进创新、创业和女性健康投资，她于2013年创立。2006年，她联合创立了Evolvence India Life Science Fund，管理该基金直到2017年7月。从2001年到2002年，Jayasuriya博士是位于帕洛阿尔托的Skyline Ventures的合伙人，此前是位于旧金山的德国/美国风险投资公司TVM的合伙人。她曾担任Genomics Collaborative，Inc.的业务开发副总裁（从1999年到2000年），以及Hoffman-La Roche的全球药物开发副总裁（从1994年到1998年）。Jayasuriya博士以优异成绩获得哈佛大学工商管理硕士学位。剑桥大学药理学博士，哈佛医学院微生物学和分子遗传学硕士，哈佛商学院工商管理硕士。
Anula Jayasuriya,Previously in 2013, Dr. Jayasuriya founded EXXclaim Capital, also focusing on Women's Health. Since May 2021, she has served on the board of directors of Lineage Cell Therapeutics, Inc. (NYSE: LCTX). In 2006, she co-founded the Evolvence India Life Science Fund, managing the fund until July of 2017. From 2001 to 2002, Dr. Jayasuriya was a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP, Business Development at Genomics Collaborative, Inc., from 1999 to 2000, VP, Global Drug Development at Hoffman-La Roche from 1994 to 1998 and Director, Outcomes Research at Syntex Laboratories. Dr. Jayasuriya received a B.A. from Harvard University summa cum laude, a M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School. - Anula Jayasuriya是ExxClaim Capital的创始人兼董事总经理，这是一家早期风险基金，专注于促进创新、创业和女性健康投资，她于2013年创立。2006年，她联合创立了Evolvence India Life Science Fund，管理该基金直到2017年7月。从2001年到2002年，Jayasuriya博士是位于帕洛阿尔托的Skyline Ventures的合伙人，此前是位于旧金山的德国/美国风险投资公司TVM的合伙人。她曾担任Genomics Collaborative，Inc.的业务开发副总裁（从1999年到2000年），以及Hoffman-La Roche的全球药物开发副总裁（从1994年到1998年）。Jayasuriya博士以优异成绩获得哈佛大学工商管理硕士学位。剑桥大学药理学博士，哈佛医学院微生物学和分子遗传学硕士，哈佛商学院工商管理硕士。
- Anula Jayasuriya,Previously in 2013, Dr. Jayasuriya founded EXXclaim Capital, also focusing on Women's Health. Since May 2021, she has served on the board of directors of Lineage Cell Therapeutics, Inc. (NYSE: LCTX). In 2006, she co-founded the Evolvence India Life Science Fund, managing the fund until July of 2017. From 2001 to 2002, Dr. Jayasuriya was a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP, Business Development at Genomics Collaborative, Inc., from 1999 to 2000, VP, Global Drug Development at Hoffman-La Roche from 1994 to 1998 and Director, Outcomes Research at Syntex Laboratories. Dr. Jayasuriya received a B.A. from Harvard University summa cum laude, a M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School.
- John Micek III
-
John Micek III，他是法学博士学位。2001年6月以来，他曾一直担任公司的董事。2011年以来，他曾一直担任Enova Systems公司（电动汽车市场的驱动系统和组件的开发商）的首席财务官。从2000年到2010年，他曾担任Silicon Prairie Partners公司（风险基金）的董事总经理。1998年9月以来，他也曾担任JAL Enterprises公司（原为Universal Assurors公司，中西部地区保险公司Universal Group的成员公司）的董事会成员。从1997年7月到1998年7月，他曾担任Protozoa公司（数字媒体与动画公司）的首席运营官。从1994年4月到1997年2月，他曾担任Enova Systems公司（移动和固定的应用程序的数字电力管理和转换系统为的开发商和制造商）的总法律顾问。他也担任Armanino Foods of Distinction公司（上市公司，生产和销售冷冻和冷藏食品）的董事。他于1974年获得Santa Clara大学的历史学士学位，并于1979年获得San Francisco大学的法学院的法学博士学位。
John Micek III,From 2000 to 2010, Mr. Micek was managing director of Silicon Prairie Partners, LP, a Palo Alto, California based family-owned venture fund. Since 2010, Mr. Micek serves on the board of directors of Armanino Foods of Distinction. He was also a board member and the Chief Executive Officer and Chief Financial Officer of Enova Systems. From March 2014 to August 2015, he served as interim Chief Financial Officer for Smith Electric Vehicles, Inc. Mr. Micek is a cum laude graduate of Santa Clara University and the University of San Francisco School of Law where he was an Articles Editor of the Law Review. His CA law license where he specialized in financial services is currently inactive. Mr. Micek has served as an adjunct professor at the University of San Francisco, teaching Corporate Governance and Ethics at the graduate school of Economics course at the University of San Francisco. - John Micek III，他是法学博士学位。2001年6月以来，他曾一直担任公司的董事。2011年以来，他曾一直担任Enova Systems公司（电动汽车市场的驱动系统和组件的开发商）的首席财务官。从2000年到2010年，他曾担任Silicon Prairie Partners公司（风险基金）的董事总经理。1998年9月以来，他也曾担任JAL Enterprises公司（原为Universal Assurors公司，中西部地区保险公司Universal Group的成员公司）的董事会成员。从1997年7月到1998年7月，他曾担任Protozoa公司（数字媒体与动画公司）的首席运营官。从1994年4月到1997年2月，他曾担任Enova Systems公司（移动和固定的应用程序的数字电力管理和转换系统为的开发商和制造商）的总法律顾问。他也担任Armanino Foods of Distinction公司（上市公司，生产和销售冷冻和冷藏食品）的董事。他于1974年获得Santa Clara大学的历史学士学位，并于1979年获得San Francisco大学的法学院的法学博士学位。
- John Micek III,From 2000 to 2010, Mr. Micek was managing director of Silicon Prairie Partners, LP, a Palo Alto, California based family-owned venture fund. Since 2010, Mr. Micek serves on the board of directors of Armanino Foods of Distinction. He was also a board member and the Chief Executive Officer and Chief Financial Officer of Enova Systems. From March 2014 to August 2015, he served as interim Chief Financial Officer for Smith Electric Vehicles, Inc. Mr. Micek is a cum laude graduate of Santa Clara University and the University of San Francisco School of Law where he was an Articles Editor of the Law Review. His CA law license where he specialized in financial services is currently inactive. Mr. Micek has served as an adjunct professor at the University of San Francisco, teaching Corporate Governance and Ethics at the graduate school of Economics course at the University of San Francisco.
高管简历
中英对照 | 中文 | 英文- Lisa A. Conte
Lisa A. Conte，自2001年11月成立Napo以来，担任首席执行官和董事会成员；自2021年3月成立以来，担任Jaguar Health， Inc.控股子公司Napo Therapeutics， S.p.A （f/k/a Napo EU S.p.A）（“Napo Therapeutics”）的董事会主席。1989年，她创立了Shaman Pharmaceuticals， Inc.，这是一家天然产品制药公司。她目前也是加州非营利公益公司Healing Forest Conservatory的董事会成员，并担任Life Science Leader杂志的编辑顾问委员会和Pure Earth领导委员会的成员。Conte女士持有California大学， San Diego的生理学和药理学硕士学位，以及Dartmouth College的生物化学工商管理硕士和学士学位。
Lisa A. Conte,serves as the Chief Executive Officer and a member of the board of Napo since she founded Napo in November 2001 and is the Chairman of the board of Jaguar Health, Inc. majority owned subsidiary Napo Therapeutics, S.p.A. (f/k/a Napo EU S.p.A.) ("Napo Therapeutics") since its inception in March 2021. In 1989, Ms. Conte founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company. Ms. Conte is also currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation, and serves on the Editorial Advisory Board of Life Science Leader magazine and on the Leadership Council of Pure Earth. Ms. Conte holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College.- Lisa A. Conte，自2001年11月成立Napo以来，担任首席执行官和董事会成员；自2021年3月成立以来，担任Jaguar Health， Inc.控股子公司Napo Therapeutics， S.p.A （f/k/a Napo EU S.p.A）（“Napo Therapeutics”）的董事会主席。1989年，她创立了Shaman Pharmaceuticals， Inc.，这是一家天然产品制药公司。她目前也是加州非营利公益公司Healing Forest Conservatory的董事会成员，并担任Life Science Leader杂志的编辑顾问委员会和Pure Earth领导委员会的成员。Conte女士持有California大学， San Diego的生理学和药理学硕士学位，以及Dartmouth College的生物化学工商管理硕士和学士学位。
- Lisa A. Conte,serves as the Chief Executive Officer and a member of the board of Napo since she founded Napo in November 2001 and is the Chairman of the board of Jaguar Health, Inc. majority owned subsidiary Napo Therapeutics, S.p.A. (f/k/a Napo EU S.p.A.) ("Napo Therapeutics") since its inception in March 2021. In 1989, Ms. Conte founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company. Ms. Conte is also currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation, and serves on the Editorial Advisory Board of Life Science Leader magazine and on the Leadership Council of Pure Earth. Ms. Conte holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College.
- Steven R. King
Steven R. King，曾担任Jaguar Health, Inc.的董事。自2012年3月起担任可持续供应、民族植物学研究和知识产权的执行副总裁。2014年9月起担任秘书。他于2020年3月晋升为可持续供应、民族植物学研究和知识产权主管。2002年至2014年，他担任Jaguar Health, Inc.全资子公司Napo Pharmaceuticals, Inc.的可持续供应、民族植物学研究和知识产权高级副总裁。在此之前，他曾担任Shaman Pharmaceuticals, Inc.的民族植物学和保护副总裁。King博士被国际天然产品和保护共同体认可，因为他创造和传播了关于Croton lechleri长期可持续收获和管理的研究，Croton lechleri是crofelemer的广泛来源。King博士目前是加州非营利公益公司Healing Forest Conservatory的董事会成员。King博士拥有New York Botanical Garden/City University经济植物学研究所的生物学博士学位和New York Botanical Garden/City University经济植物学研究所的生物学硕士学位。
Steven R. King,was promoted to Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property in March 2020. From 2002 to 2012, Dr. King served as the Senior Vice President of Sustainable Supply, Ethnobotanical Research and Intellectual Property at Jaguar Health, Inc. wholly-owned subsidiary, Napo Pharmaceuticals, Inc. Prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds a Ph.D. in Biology from the Institute of Economic Botany of the New York Botanical Garden/City University of New York and an M.S. in Biology from the Institute of Economic Botany of the New York Botanical Garden/City University of New York.- Steven R. King，曾担任Jaguar Health, Inc.的董事。自2012年3月起担任可持续供应、民族植物学研究和知识产权的执行副总裁。2014年9月起担任秘书。他于2020年3月晋升为可持续供应、民族植物学研究和知识产权主管。2002年至2014年，他担任Jaguar Health, Inc.全资子公司Napo Pharmaceuticals, Inc.的可持续供应、民族植物学研究和知识产权高级副总裁。在此之前，他曾担任Shaman Pharmaceuticals, Inc.的民族植物学和保护副总裁。King博士被国际天然产品和保护共同体认可，因为他创造和传播了关于Croton lechleri长期可持续收获和管理的研究，Croton lechleri是crofelemer的广泛来源。King博士目前是加州非营利公益公司Healing Forest Conservatory的董事会成员。King博士拥有New York Botanical Garden/City University经济植物学研究所的生物学博士学位和New York Botanical Garden/City University经济植物学研究所的生物学硕士学位。
- Steven R. King,was promoted to Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property in March 2020. From 2002 to 2012, Dr. King served as the Senior Vice President of Sustainable Supply, Ethnobotanical Research and Intellectual Property at Jaguar Health, Inc. wholly-owned subsidiary, Napo Pharmaceuticals, Inc. Prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds a Ph.D. in Biology from the Institute of Economic Botany of the New York Botanical Garden/City University of New York and an M.S. in Biology from the Institute of Economic Botany of the New York Botanical Garden/City University of New York.
- Carol R. Lizak
Carol R. Lizak，自2021年4月起担任Jaguar Health, Inc.首席财务官。她于2019年5月加入公司，担任财务副总裁兼公司财务总监，2019年8月晋升为首席会计官,2020年3月晋升为财务高级副总裁兼首席会计官。在加入Jaguar Health, Inc.之前，Lizak女士于2017年11月至2019年1月担任Zosano Pharma Corporation高级董事兼公司财务总监，2016年7月至2017年8月担任Quantum Secure公司财务总监，2014年9月至2016年7月担任阿莱克萨制药公司执行董事兼公司财务总监。在此之前，她在HID全球公司的一家子公司担任了九年的公司财务总监。Lizak女士拥有佩珀代因大学Graziadio商业与管理学院工商管理硕士学位和圣托马斯大学工商管理学士学位。
Carol R. Lizak,joined the Company in May 2019 as Vice President of Finance and Corporate Controller and was promoted to Chief Accounting Officer in August 2019 and Senior Vice-President of Finance and Chief Accounting Officer in March 2020. Prior to joining Jaguar Health, Inc. , Ms. Lizak served as Senior Director and Corporate Controller of Zosano Pharma Corporation from November 2017 to January 2019, as Controller of Quantum Secure, Inc. from July 2016 to August 2017, and as Executive Director, Corporate Controller of Alexza Pharmaceuticals, Inc. from September 2014 to July 2016. Prior thereto, she spent nine years as Corporate Controller of a subsidiary of HID Global Corporation. Ms. Lizak holds an M.B.A from Pepperdine University, Graziadio School of Business and Management and a B.S. in Business Administration from the University of Santo Tomas.- Carol R. Lizak，自2021年4月起担任Jaguar Health, Inc.首席财务官。她于2019年5月加入公司，担任财务副总裁兼公司财务总监，2019年8月晋升为首席会计官,2020年3月晋升为财务高级副总裁兼首席会计官。在加入Jaguar Health, Inc.之前，Lizak女士于2017年11月至2019年1月担任Zosano Pharma Corporation高级董事兼公司财务总监，2016年7月至2017年8月担任Quantum Secure公司财务总监，2014年9月至2016年7月担任阿莱克萨制药公司执行董事兼公司财务总监。在此之前，她在HID全球公司的一家子公司担任了九年的公司财务总监。Lizak女士拥有佩珀代因大学Graziadio商业与管理学院工商管理硕士学位和圣托马斯大学工商管理学士学位。
- Carol R. Lizak,joined the Company in May 2019 as Vice President of Finance and Corporate Controller and was promoted to Chief Accounting Officer in August 2019 and Senior Vice-President of Finance and Chief Accounting Officer in March 2020. Prior to joining Jaguar Health, Inc. , Ms. Lizak served as Senior Director and Corporate Controller of Zosano Pharma Corporation from November 2017 to January 2019, as Controller of Quantum Secure, Inc. from July 2016 to August 2017, and as Executive Director, Corporate Controller of Alexza Pharmaceuticals, Inc. from September 2014 to July 2016. Prior thereto, she spent nine years as Corporate Controller of a subsidiary of HID Global Corporation. Ms. Lizak holds an M.B.A from Pepperdine University, Graziadio School of Business and Management and a B.S. in Business Administration from the University of Santo Tomas.
- Jonathan S. Wolin
Jonathan S. Wolin，自2019年9月4日起担任Jaguar Health, Inc.办公室主任兼总法律顾问。他于2018年11月加入公司，担任公司首席合规官和公司法律顾问，并继续担任首席合规官。在加入本公司之前，Wolin先生于2017年6月至2018年11月担任独立顾问，就公司合规问题向客户提供咨询；于2016年9月至2017年5月担任Braden Partners首席行政官（太平洋肺脏服务）；于2015年6月至2016年8月担任Natera公司首席合规官；于2013年9月至2015年5月担任Braden Partners首席合规官。沃林拥有美国天主教大学哥伦布法学院法学博士学位、乔治华盛顿大学商学院工商管理硕士学位和马里兰大学会计学学士学位。
Jonathan S. Wolin,joined the Company in November 2018 as Chief Compliance Officer and Corporate Counsel of the Company and continues to serve as Chief Compliance Officer. Prior to joining the Company, Mr. Wolin served as an independent consultant advising clients on corporate compliance from June 2017 to November 2018, as Chief Administrative Officer of Braden Partners (d/b/a Pacific Pulmonary Services) from September 2016 to May 2017, as Chief Compliance Officer of Natera, Inc. from June 2015 to August 2016, and as Chief Compliance Officer of Braden Partners from September 2013 to May 2015. Mr. Wolin holds a J.D. from The Catholic University of America, Columbus School of Law, an M.B.A. from The George Washington University School of Business and a B.S. in Accounting from the University of Maryland.- Jonathan S. Wolin，自2019年9月4日起担任Jaguar Health, Inc.办公室主任兼总法律顾问。他于2018年11月加入公司，担任公司首席合规官和公司法律顾问，并继续担任首席合规官。在加入本公司之前，Wolin先生于2017年6月至2018年11月担任独立顾问，就公司合规问题向客户提供咨询；于2016年9月至2017年5月担任Braden Partners首席行政官（太平洋肺脏服务）；于2015年6月至2016年8月担任Natera公司首席合规官；于2013年9月至2015年5月担任Braden Partners首席合规官。沃林拥有美国天主教大学哥伦布法学院法学博士学位、乔治华盛顿大学商学院工商管理硕士学位和马里兰大学会计学学士学位。
- Jonathan S. Wolin,joined the Company in November 2018 as Chief Compliance Officer and Corporate Counsel of the Company and continues to serve as Chief Compliance Officer. Prior to joining the Company, Mr. Wolin served as an independent consultant advising clients on corporate compliance from June 2017 to November 2018, as Chief Administrative Officer of Braden Partners (d/b/a Pacific Pulmonary Services) from September 2016 to May 2017, as Chief Compliance Officer of Natera, Inc. from June 2015 to August 2016, and as Chief Compliance Officer of Braden Partners from September 2013 to May 2015. Mr. Wolin holds a J.D. from The Catholic University of America, Columbus School of Law, an M.B.A. from The George Washington University School of Business and a B.S. in Accounting from the University of Maryland.
- Pravin Chaturvedi
Pravin Chaturvedi，自2022年3月1日起继续担任公司科学顾问委员会（SAB）主席，并担任Jaguar Health, Inc.首席科学官。他于2017年5月加入公司，担任Jaguar和Napo的SAB主席。在制药行业30多年的职业生涯中，Chaturvedi博士参与了癫痫、艾滋病毒、丙肝、记忆和胃肠道疾病治疗领域多种药物的成功开发和商业化。Chaturvedi博士在2006年至2013年期间担任Napo的总裁兼首席科学官，并在2013年至2017年期间继续担任Napo的科学顾问。Chaturvedi博士与他人共同创立并领导了多家生物技术企业。2001年至2004年，他担任Scion Pharmaceuticals，Inc.的总裁、首席执行官和董事。他是IndUS Pharmaceuticals的创始人，自2017年起担任该公司董事长和董事，并在2005年至2007年和2010年至2015年担任相同职务。IndUS Pharmaceuticals于2015年与Pivot Pharmaceuticals合并，Chaturvedi博士在2015年至2017年担任Pivot Pharmaceuticals总裁兼首席执行官，之后担任Napo和Jaguar的SAB主席。Chaturvedi博士还与他人共同创立了Oceanyx Pharmaceuticals，自2011年起担任该公司首席执行官和董事，并继续在IndUS、Oceanyx、Enlivity和Cellanyx的董事会任职。自2013年以来，他一直是乔治城大学的兼职教员。在其职业生涯的早期，从1994年到2001年，Chaturvedi博士在福泰制药担任过各种职务，担任首席评价主管，从1993年到1994年，他在阿尔凯默斯公司的临床前小组工作。1988年，他在Parke-Davis/Warner-Lambert公司（现为辉瑞）的产品开发小组开始了他的职业生涯，并在那里工作到1993年。Chaturvedi博士拥有西弗吉尼亚大学药学博士学位和孟买大学药学学士学位。
Pravin Chaturvedi,joined the Company in May 2017 as Chair of the SAB of Jaguar and Napo. Over his more-than-30-year career in the pharmaceutical industry, Dr. Chaturvedi has participated in the successful development and commercialization of multiple drugs in the therapeutic areas of epilepsy, HIV, hepatitis C, memory and gastrointestinal disorders. Dr. Chaturvedi served as the President and Chief Scientific Officer of Napo from 2006 to 2013 and remained a scientific adviser of Napo from 2013 through 2017. Dr. Chaturvedi has co-founded and led multiple biotech enterprises. From 2001 through 2004, he served as the President, Chief Executive Officer and Director of Scion Pharmaceuticals, Inc. He is the founder of IndUS Pharmaceuticals, where he has served as Chairman and Director since 2017, and held the same roles from 2005 through 2007 and from 2010 through 2015. IndUS Pharmaceuticals merged with Pivot Pharmaceuticals in 2015 and Dr. Chaturvedi served as the President and CEO of Pivot Pharmaceuticals from 2015 to 2017, prior to assuming his role as the Chair of the SAB for Napo and Jaguar. Dr. Chaturvedi also co-founded Oceanyx Pharmaceuticals, where he has served as Chief Executive Officer and Director since 2011, and he continues to serve on the boards of IndUS, Oceanyx, Enlivity and Cellanyx. He has been an adjunct faculty member at Georgetown University since 2013. Earlier in his career, from 1994 through 2001, Dr. Chaturvedi served in various roles as the head of lead evaluation at Vertex Pharmaceuticals, and from 1993 through 1994 he was in the preclinical group at Alkermes Inc. He started his career in the product development group at Parke-Davis/ Warner-Lambert Company (now Pfizer) in 1988, where he worked through 1993. Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor's in Pharmacy from the University of Bombay. Dr. Chaturvedi received a lifetime achievement award in 2022 from the biotech industry.- Pravin Chaturvedi，自2022年3月1日起继续担任公司科学顾问委员会（SAB）主席，并担任Jaguar Health, Inc.首席科学官。他于2017年5月加入公司，担任Jaguar和Napo的SAB主席。在制药行业30多年的职业生涯中，Chaturvedi博士参与了癫痫、艾滋病毒、丙肝、记忆和胃肠道疾病治疗领域多种药物的成功开发和商业化。Chaturvedi博士在2006年至2013年期间担任Napo的总裁兼首席科学官，并在2013年至2017年期间继续担任Napo的科学顾问。Chaturvedi博士与他人共同创立并领导了多家生物技术企业。2001年至2004年，他担任Scion Pharmaceuticals，Inc.的总裁、首席执行官和董事。他是IndUS Pharmaceuticals的创始人，自2017年起担任该公司董事长和董事，并在2005年至2007年和2010年至2015年担任相同职务。IndUS Pharmaceuticals于2015年与Pivot Pharmaceuticals合并，Chaturvedi博士在2015年至2017年担任Pivot Pharmaceuticals总裁兼首席执行官，之后担任Napo和Jaguar的SAB主席。Chaturvedi博士还与他人共同创立了Oceanyx Pharmaceuticals，自2011年起担任该公司首席执行官和董事，并继续在IndUS、Oceanyx、Enlivity和Cellanyx的董事会任职。自2013年以来，他一直是乔治城大学的兼职教员。在其职业生涯的早期，从1994年到2001年，Chaturvedi博士在福泰制药担任过各种职务，担任首席评价主管，从1993年到1994年，他在阿尔凯默斯公司的临床前小组工作。1988年，他在Parke-Davis/Warner-Lambert公司（现为辉瑞）的产品开发小组开始了他的职业生涯，并在那里工作到1993年。Chaturvedi博士拥有西弗吉尼亚大学药学博士学位和孟买大学药学学士学位。
- Pravin Chaturvedi,joined the Company in May 2017 as Chair of the SAB of Jaguar and Napo. Over his more-than-30-year career in the pharmaceutical industry, Dr. Chaturvedi has participated in the successful development and commercialization of multiple drugs in the therapeutic areas of epilepsy, HIV, hepatitis C, memory and gastrointestinal disorders. Dr. Chaturvedi served as the President and Chief Scientific Officer of Napo from 2006 to 2013 and remained a scientific adviser of Napo from 2013 through 2017. Dr. Chaturvedi has co-founded and led multiple biotech enterprises. From 2001 through 2004, he served as the President, Chief Executive Officer and Director of Scion Pharmaceuticals, Inc. He is the founder of IndUS Pharmaceuticals, where he has served as Chairman and Director since 2017, and held the same roles from 2005 through 2007 and from 2010 through 2015. IndUS Pharmaceuticals merged with Pivot Pharmaceuticals in 2015 and Dr. Chaturvedi served as the President and CEO of Pivot Pharmaceuticals from 2015 to 2017, prior to assuming his role as the Chair of the SAB for Napo and Jaguar. Dr. Chaturvedi also co-founded Oceanyx Pharmaceuticals, where he has served as Chief Executive Officer and Director since 2011, and he continues to serve on the boards of IndUS, Oceanyx, Enlivity and Cellanyx. He has been an adjunct faculty member at Georgetown University since 2013. Earlier in his career, from 1994 through 2001, Dr. Chaturvedi served in various roles as the head of lead evaluation at Vertex Pharmaceuticals, and from 1993 through 1994 he was in the preclinical group at Alkermes Inc. He started his career in the product development group at Parke-Davis/ Warner-Lambert Company (now Pfizer) in 1988, where he worked through 1993. Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor's in Pharmacy from the University of Bombay. Dr. Chaturvedi received a lifetime achievement award in 2022 from the biotech industry.